|
2024
|
Invention
|
Cnp prodrugs with large carrier moieties.
The present invention relates to a CNP prodrug or a ph... |
|
|
Invention
|
Controlled-release cnp agonists with low initial npr-b activity.
The present invention relates t... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of growth disorders; pharmaceutical preparations fo... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of growth
disorders; pharmaceutical preparations f... |
|
|
Invention
|
Cnp prodrugs with carrier attachment at the ring moiety.
The present invention relates to CNP pr... |
|
|
Invention
|
Cnp prodrugs.
The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pha... |
|
|
Invention
|
Controlled-release cnp agonists with increased nep stability.
The present invention relates to c... |
|
|
G/S
|
Pharmaceutical preparations for the treatment, in relation to the following fields: Growth-relate... |
|
|
Invention
|
Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia. The pres... |
|
2023
|
Invention
|
Method of improving skeletal muscle function. The present invention relates to methods of improvi... |
|
|
Invention
|
Liquid pharmaceutical formulations of cnp compounds.
A liquid pharmaceutical formulation compris... |
|
|
Invention
|
Liquid pharmaceutical formulations of cnp compounds. A liquid pharmaceutical formulation comprisi... |
|
2022
|
Invention
|
Combination therapy with controlled-release cnp agonists.
The present invention relates to a com... |
|
|
Invention
|
Effective doses of cnp conjugates.
The present invention relates to unit dosage forms comprising... |
|
|
Invention
|
Effective doses of cnp conjugates. The present invention relates to unit dosage forms comprising ... |
|
|
Invention
|
Cnp prodrugs with carrier attachment at the ring moiety. The present invention relates to CNP pro... |
|
|
Invention
|
Controlled-release cnp agonists with low initial npr-b activity. 50 of the corresponding free CNP... |
|
|
Invention
|
Controlled-release cnp agonists with reduced side-effects.
The present invention relates a pharm... |
|
|
Invention
|
Controlled-release cnp agonists with low npr-c binding.
The present invention relates to a contr... |
|
2021
|
Invention
|
Controlled-release cnp agonists with increased nep stability. The present invention relates to co... |
|
|
Invention
|
Cnp prodrugs with large carrier moieties. 2- is a chemical bond or a spacer; and —Z is a polymer ... |
|
2020
|
Invention
|
Dry pharmaceutical formulations of cnp conjugates. A dry pharmaceutical formulation, wherein the ... |
|
2017
|
Invention
|
Combination therapy with controlled-release cnp agonists. The present invention relates to a comb... |
|
|
Invention
|
Controlled-release cnp agonists with reduced side-effects. The present invention relates a pharma... |
|
|
Invention
|
Controlled-release cnp agonists with low npr-c binding. The present invention relates to a contro... |
|
|
Invention
|
Cnp prodrugs with large carrier moieties. The present invention relates to a CNP prodrug or a pha... |
|
|
Invention
|
Controlled-release cnp agonists with low initial npr-b activity. The present invention relates to... |
|
2016
|
Invention
|
Cnp prodrugs. The present invention relates to prodrugs of C-type natriuretic peptide (CNP), phar... |
